SSA
ODT

Schonfeld Strategic Advisors’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-49,900
Closed -$174K – 2646
2021
Q2 		$174K Sell
49,900
-170,576
-77% -$586K ﹤0.01% 1712
2021
Q1 		$754K Buy
+220,476
New +$4.17M 0.01% 995

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schonfeld Strategic Advisors's ODT Position: Q3 2021 in Review

Schonfeld Strategic Advisors sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2021, closing a stake of 49,900 shares — an estimated $174K sold.

Schonfeld Strategic Advisors first reported a position in ODT in Q1 2021 and held it in 2 quarters. The position peaked at $754K in Q1 2021. 58 funds tracked by Wall St. Rank hold ODT as of Q3 2021.

  • Schonfeld Strategic Advisors reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 49,900 Odonate Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $174K.
  • Schonfeld Strategic Advisors first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Odonate Therapeutics, Inc. Common Stock position peaked at $754K in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.